• Molecular Partners began dosing patients in a randomized Phase 2 trial of MP0317 with standard first-line chemoimmunotherapy in advanced cholangiocarcinoma.
• Early trial progress shows enrollment advancing as planned, with patients receiving multiple treatment cycles.
• No results have been presented yet; a trial-in-progress update is scheduled for ESMO 2026, with a data update expected in 2027.
• The study tests whether adding MP0317 can improve outcomes versus standard of care alone, aiming for deeper and longer-lasting responses.
• Trial completion is targeted for 2028, setting a multi-year timeline for clinical readouts that could shape the program’s next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-004758), on July 20, 2026, and is solely responsible for the information contained therein.